• 主页
  • 查找结果
  • Early outcomes of thulium laser versus transurethral resection of the prostate for managing benign prostatic hyperplasia: a systematic review and meta-analysis of comparative studies.

Early outcomes of thulium laser versus transurethral resection of the prostate for managing benign prostatic hyperplasia: a systematic review and meta-analysis of comparative studies.

Journal of endourology (2013-08-29)
Kun Tang, Zhengli Xu, Ding Xia, Xin Ma, Xiaolin Guo, Wei Guan, Zhiquan Hu, Xu Zhang, Zhangqun Ye, Hua Xu
摘要

To assess the efficacy and safety of thulium laser resection of the prostate (TmLRP) vs transurethral resection of the prostate (TURP) for treating patients with benign prostatic hyperplasia (BPH). A systematic search of the electronic databases, including Medline, Scopus, China National Knowledge Infrastructure, and the Cochrane Library was performed up to May 1, 2013. The pooled outcomes of interest assessing the two techniques included demographic and clinical baseline characteristics, perioperative variables, complications, and postoperative efficacy including maximum flow rate (Qmax), postvoid residual (PVR), quality of life (QoL) and International Prostate Symptom Score (IPSS). Nine trials assessing TmLRP vs. TURP were considered suitable for meta-analysis including three randomized controlled trials (RCTs), two prospective, and four retrospective studies. Compared with TURP, although TmLRP needed a longer operative time (weighted mean difference [WMD]: 9.00 min; 95% confidence interval [CI], 2.53-15.47; P=0.006), patients having TmLRP might benefit from significantly less serum sodium decreased (-3.58 mmol/L; 95% CI, -4.04 to -3.12; P<0.001), less serum hemoglobin decreased (WMD: -0.94 mmol/L; 95% CI, -1.44 to -0.44; P<0.001), shorter time of catheterization (WMD: -2.07 days; 95% CI, -2.66 to -1.49; P<0.001), shorter length of hospital stay (WMD: -1.87 days; 95% CI, -2.41 to -1.33; P<0.001), and fewer total complications (odds ratio [OR]: 0.29; 95% CI, 0.20-0.41; P<0.001). During the 1, 3, 6, and 12 months of postoperative follow-up, the procedures did not demonstrate a significant difference in Qmax, IPSS, PVR, and QoL. Our data suggest that as a promising minimally invasive technique, TmLRP appears to be a safe, feasible, and efficient alternative to TURP for treating patients with BPH with reliable perioperative safety, fewer complications, and comparable efficacy in relation to Qmax, PVR, QoL, and IPSS. Because of the inherent limitations of the included studies, further large sample prospective, multicentric, long-term follow-up studies and RCTs should be undertaken to confirm our findings.

材料
货号
品牌
产品描述

铥, wire, 0.1m, diameter 0.6mm, 99%
铥, foil, 25x25mm, thickness 0.15mm, as rolled, 99%
铥, foil, 25x25mm, thickness 0.1mm, as rolled, 99%
铥, foil, 50x50mm, thickness 0.15mm, as rolled, 99%
铥, foil, 50x50mm, thickness 0.1mm, as rolled, 99%
铥, foil, not light tested, 12.5x12.5mm, thickness 0.002mm, as rolled, 99%
铥, foil, not light tested, 12.5x12.5mm, thickness 0.005mm, as rolled, 99%
铥, foil, not light tested, 25x25mm, thickness 0.002mm, as rolled, 99%
铥, foil, not light tested, 25x25mm, thickness 0.005mm, as rolled, 99%
铥, foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%
铥, foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%
Sigma-Aldrich
铥, foil, size 25 mm × 25 mm × 1 mm, 99.9% trace rare earth metals basis

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。